Iacopo Olivotto
#145,787
Most Influential Person Now
Researcher
Iacopo Olivotto's AcademicInfluence.com Rankings
Iacopo Olivottocomputer-science Degrees
Computer Science
#7294
World Rank
#7682
Historical Rank
Machine Learning
#2648
World Rank
#2683
Historical Rank
Artificial Intelligence
#2944
World Rank
#2989
Historical Rank
Database
#4356
World Rank
#4530
Historical Rank
Download Badge
Computer Science
Iacopo Olivotto's Degrees
- PhD Computer Science University of Florence
- Masters Computer Science University of Florence
- Bachelors Computer Science University of Florence
Similar Degrees You Can Earn
Why Is Iacopo Olivotto Influential?
(Suggest an Edit or Addition)Iacopo Olivotto's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. (2003) (1200)
- Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. (2000) (816)
- Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. (2000) (758)
- Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy (2001) (712)
- Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy (2014) (698)
- Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. (2003) (682)
- Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. (2005) (662)
- Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction (2006) (648)
- Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014) (528)
- Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. (2009) (404)
- Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. (2008) (370)
- Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. (2002) (337)
- Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy (2013) (332)
- Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy (2010) (331)
- Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. (1995) (292)
- Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. (2005) (291)
- Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. (2010) (264)
- The case for myocardial ischemia in hypertrophic cardiomyopathy. (2009) (262)
- Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2008) (259)
- Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). (2018) (250)
- Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy (2018) (244)
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (239)
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study (2016) (238)
- Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. (1999) (231)
- Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. (2006) (218)
- Patterns of Disease Progression in Hypertrophic Cardiomyopathy: An Individualized Approach to Clinical Staging (2012) (216)
- Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). (2006) (209)
- Effect of aging on myocardial perfusion reserve. (1995) (178)
- Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. (2013) (154)
- Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. (2003) (150)
- Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2010) (146)
- The coronary circulation and blood flow in left ventricular hypertrophy. (2012) (137)
- Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? (2007) (135)
- Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. (2011) (134)
- Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population (1998) (133)
- Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. (2010) (133)
- Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. (2012) (132)
- Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. (2016) (132)
- Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. (2006) (130)
- Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. (2006) (124)
- International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) (2017) (121)
- Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy (2020) (115)
- Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy (2020) (114)
- Left ventricular apical ballooning syndrome as a novel cause of acute mitral regurgitation. (2007) (110)
- Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations (2014) (107)
- The familial hypertrophic cardiomyopathy‐associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils (2008) (103)
- Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. (2013) (100)
- Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity (2021) (99)
- Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. (2014) (91)
- Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). (2019) (90)
- Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation (2016) (88)
- Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives (2016) (87)
- Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts (2016) (87)
- Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. (2011) (87)
- Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. (2007) (82)
- Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. (1998) (80)
- Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy (2018) (80)
- Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease (2017) (78)
- Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study (2018) (78)
- A molecular screening strategy based on β-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy (2006) (77)
- Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis (2009) (77)
- Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. (2014) (74)
- A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy (2020) (74)
- Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy (2008) (74)
- Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. (1998) (71)
- Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy (2017) (71)
- Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction (2020) (69)
- The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice (2009) (69)
- Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. (2016) (68)
- MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. (2014) (66)
- Role of Genetic Testing in Inherited Cardiovascular Disease: A Review (2017) (64)
- Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. (2015) (64)
- Novel &agr;-Actinin 2 Variant Associated With Familial Hypertrophic Cardiomyopathy and Juvenile Atrial Arrhythmias: A Massively Parallel Sequencing Study (2014) (62)
- Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. (2015) (59)
- Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. (2019) (59)
- An expert consensus document on the management of cardiovascular manifestations of Fabry disease (2020) (59)
- Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment (2010) (59)
- Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). (2003) (58)
- Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events (2018) (57)
- β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. (2012) (57)
- Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. (2013) (55)
- Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models (2017) (55)
- Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. (1997) (55)
- Determinants of echocardiographic left atrial volume: implications for normalcy. (2011) (55)
- Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. (1996) (54)
- Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. (2021) (54)
- Role of Exercise Testing in Hypertrophic Cardiomyopathy. (2017) (53)
- Microvascular Dysfunction, Myocardial Ischemia, and Progression to Heart Failure in Patients with Hypertrophic Cardiomyopathy (2009) (53)
- The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. (2005) (52)
- Research priorities in sarcomeric cardiomyopathies. (2015) (51)
- Pre‐discharge B‐type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit (2005) (51)
- The spectrum of myocarditis: from pathology to the clinics (2019) (48)
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (2021) (48)
- Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. (2003) (47)
- Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial (2016) (47)
- Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience (2018) (46)
- Late sodium current inhibitors to treat exercise‐induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium (2018) (46)
- Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications (2017) (44)
- Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson–Fabry disease (2013) (44)
- Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care. (2012) (43)
- Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. (2019) (42)
- Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. (2002) (41)
- Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. (2016) (41)
- Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. (2016) (41)
- Dynamic assessment of 'valvular reserve capacity' in patients with rheumatic mitral stenosis. (2012) (40)
- The Electrocardiogram in the Diagnosis and Management of Patients with Hypertrophic Cardiomyopathy. (2019) (40)
- Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center (2018) (40)
- Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context (2018) (39)
- Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy (2015) (39)
- The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy (2020) (38)
- Improving Survival Rates of Patients With Idiopathic Dilated Cardiomyopathy in Tuscany Over 3 Decades: Impact of Evidence-Based Management (2013) (38)
- Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. (2020) (38)
- Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. (2013) (38)
- Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation (2017) (36)
- Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. (2010) (36)
- Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators (2018) (34)
- Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry. (2016) (34)
- The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. (2018) (34)
- 'End-stage' hypertrophic cardiomyopathy: from mystery to model (2007) (34)
- Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program (2012) (33)
- Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. (2004) (33)
- Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. (2018) (33)
- Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy (2021) (33)
- Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies (2021) (32)
- Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study (2021) (32)
- Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy (2019) (31)
- The incremental prognostic value of pharmacological stress echo over exercise electrocardiography in women with chest pain of unknown origin. (2001) (31)
- Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. (2013) (31)
- Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. (2020) (31)
- Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. (2019) (31)
- Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy (2017) (31)
- Abnormalities in Sodium Current and Calcium Homeostasis as Drivers of Arrhythmogenesis in Hypertrophic Cardiomyopathy. (2020) (30)
- Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (&bgr;-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy (2017) (29)
- Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study (2017) (28)
- Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy (2001) (27)
- PROGNOSTIC UTILITY OF CONTRAST-ENHANCED CARDIOVASCULAR MAGNETIC RESONANCE IN HYPERTROPHIC CARDIOMYOPATHY: AN INTERNATIONAL MULTICENTER STUDY (2012) (27)
- Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure. (1995) (26)
- Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing? (2020) (26)
- Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. (2016) (25)
- Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy (2021) (25)
- Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. (2021) (25)
- Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. (2017) (25)
- Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. (2020) (24)
- Regulation of intracellular Na+ in health and disease: pathophysiological mechanisms and implications for treatment (2013) (24)
- Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy (2020) (24)
- Clinical and molecular classification of cardiomyopathies (2012) (23)
- Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy (2020) (23)
- Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. (1996) (23)
- The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? (2006) (23)
- Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey (2022) (23)
- Life-long tailoring of management for patients with hypertrophic cardiomyopathy (2016) (23)
- Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. (2020) (23)
- Systemic arterial waveform analysis and assessment of blood flow during extracorporeal circulation (2006) (22)
- Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy (2009) (22)
- Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C (2013) (22)
- Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. (2006) (22)
- Reevaluation of the South Asian MYBPC3Δ25bp Intronic Deletion in Hypertrophic Cardiomyopathy (2020) (21)
- Long term complications in patients implanted with subcutaneous implantable defibrillators Real-world data from the Extended ELISIR experience. (2021) (21)
- Functional assessment of cutaneous microvasculature after radiation. (1999) (21)
- Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy (2006) (21)
- Associations Between Female Sex, Sarcomere Variants and Clinical Outcomes in Hypertrophic Cardiomyopathy. (2020) (20)
- Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®). (2017) (20)
- Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease (2017) (19)
- Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy. (1999) (19)
- Prospective evaluation of adenosine-induced proarrhythmia in the emergency room (2001) (19)
- Appropriate and Inappropriate Shocks in Hypertrophic Cardiomyopathy Patients with Subcutaneous Implantable Cardioverter Defibrillators: An International Multi-Center Study. (2020) (19)
- Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. (2007) (18)
- Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. (2019) (18)
- Clinical profile and outcome of cardiac involvement in MELAS syndrome. (2019) (18)
- Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal (2016) (18)
- Clinical Profile of Cardiac Involvement in Danon Disease (2020) (18)
- Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy (2020) (18)
- Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. (2021) (18)
- Study Design and Rationale of EXPLORER-HCM (2020) (17)
- Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions (2020) (17)
- New concepts in hypertrophic cardiomyopathies. (2002) (17)
- Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. (2022) (17)
- Therapeutic implications of contractile reserve elicited by dobutamine echocardiography in symptomatic, low-gradient aortic stenosis. (2003) (16)
- Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. (2019) (16)
- Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy (2020) (16)
- Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. (2020) (16)
- Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis (2012) (16)
- A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. (2021) (16)
- Minimally invasive and noninvasive hemodynamic monitoring of the cardiovascular system: Available options and future perspectives (2006) (16)
- Complete neurological recovery after systemic air embolism during endoscopic retrograde cholangiopancreatography. (2012) (16)
- Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. (2021) (16)
- An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy (2015) (15)
- Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis. (2022) (15)
- Distal extremity pain as a presenting feature of Fabry's disease (2011) (15)
- Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy (2017) (15)
- Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria. (2018) (15)
- Chest pain unit management of patients at low and not low-risk for coronary artery disease in the emergency department. A 5-year experience in the Florence area (2002) (14)
- Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy (2019) (14)
- Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy. (2010) (14)
- Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas: an emerging problem in Europe (2015) (14)
- Calcified left ventricular endomyocardial fibrosis. (2012) (13)
- Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience (2021) (13)
- Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy (2015) (13)
- Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) (2020) (13)
- Effect of left ventricular outflow tract in hypertrophic cardiomyopathy (2003) (13)
- Response to letter regarding article, "Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy". (2013) (13)
- Emerging Medical Treatment for Hypertrophic Cardiomyopathy (2021) (13)
- Hypertrophic cardiomyopathy in the community: why we should care (2005) (12)
- Acute Myocarditis Associated With Desmosomal Gene Variants. (2022) (12)
- Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study. (2017) (12)
- Hypertrophic cardiomyopathy: The need for randomized trials (2013) (12)
- Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center (2021) (12)
- Targeted Medical Therapies for Hypertrophic Cardiomyopathy (2020) (12)
- Heritability in genetic heart disease: the role of genetic background (2019) (12)
- Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil. (2009) (12)
- External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy (2021) (12)
- Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy (2012) (12)
- Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. (2018) (12)
- Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study (2017) (12)
- Clinical presentation and long‐term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study (2021) (12)
- A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy (2021) (12)
- Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives (2021) (11)
- The Left Ventricular Outflow in Hypertrophic Cardiomyopathy: From Structure to Function (2009) (11)
- Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre. (2020) (11)
- The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy (2021) (11)
- Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different? (2015) (11)
- Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy (2021) (11)
- Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry (2020) (11)
- Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability (2021) (11)
- 839-1 The long-term effect of surgical myectomy on survival in patients with obstructive hypertrophic cardiomyopathy (2004) (10)
- Quality control of B-lines analysis in stress Echo 2020 (2018) (10)
- Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study (2021) (10)
- Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. (2021) (10)
- Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator (2022) (10)
- LONG-TERM SAFETY OF MAVACAMTEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS OF THE MAVA-LONG TERM EXTENSION (LTE) STUDY (2021) (10)
- Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy (2009) (10)
- Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. (2020) (9)
- Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre (2021) (9)
- Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study (2019) (9)
- Subcutaneous implantable cardioverter defibrillator and defibrillation testing: a propensity-matched pilot study. (2021) (9)
- Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. (2021) (9)
- Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis (2022) (8)
- Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes (2022) (8)
- Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. (2023) (8)
- Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients (2021) (8)
- Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. (1997) (8)
- Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy (2022) (8)
- Generation of virtual patient data for in-silico cardiomyopathies drug development using tree ensembles: a comparative study (2020) (7)
- Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates (2020) (7)
- Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype (2020) (7)
- INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) (2015) (7)
- Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time. (2020) (7)
- Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy (2020) (7)
- On the Cardiac Loop and Its Failing: Left Ventricular Outflow Tract Obstruction (2020) (7)
- Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death. (2021) (7)
- Channelopathies, cardiac hypertrophy, and the theory of light. (2018) (7)
- Sex-related differences in ventricular remodeling after myocardial infarction. (2021) (7)
- [Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine]. (2012) (7)
- Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. (2020) (7)
- Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. (2021) (7)
- Sport practice in hypertrophic cardiomyopathy: Running to stand still? (2021) (7)
- Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging (2021) (6)
- Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important? (2009) (6)
- Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation (2020) (6)
- The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. (2003) (6)
- Clinical presentations leading to arrhythmogenic left ventricular cardiomyopathy (2022) (6)
- Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials. (2018) (6)
- Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy (2020) (6)
- Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy (2007) (6)
- Optical Coherence Tomography Angiography in Fabry disease (2018) (6)
- Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long‐term results and clinical outcomes (2021) (6)
- EMBOLIC RISK STRATIFICATION ANDPROGNOSTIC IMPACT OF EARLY SURGERY IN LEFT-SIDED INFECTIVE ENDOCARDITIS. (2020) (6)
- Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside (2022) (5)
- [Clinical course of hypertrophic cardiomyopathy in a non selected population. The Experience of the Italian Multicenter Cardiomyopathy Study]. (1997) (5)
- Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis. (2020) (5)
- Sex‐Related Differences in Genetic Cardiomyopathies (2022) (5)
- The Effect of Aging On Coronary Flow Reserve in Man (1993) (5)
- Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study. (2020) (5)
- Assessment of blood flow during extra-corporeal circulation from arterial waveform analysis (2004) (5)
- Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing. (2021) (5)
- Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time. (2020) (5)
- A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains (2021) (5)
- Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (2020) (5)
- Clinical characteristics and natural history of PRKAG2 syndrome (2020) (4)
- Poster session 2 (2004) (4)
- Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. (2022) (4)
- Racial Differences in Val122Ile associated Transthyretin Cardiac Amyloidosis. (2021) (4)
- Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy (2021) (4)
- Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders (2020) (4)
- Neither Athletic Training nor Detraining Affects LV Hypertrophy in Adult, Low-Risk Patients With HCM. (2021) (4)
- Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathy—An Analysis from the SILICOFCM Database (2022) (4)
- Common presentation of rare cardiac diseases: Arrhythmias. (2018) (4)
- Erratum to: Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program (2013) (4)
- Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations (2022) (4)
- IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. (2019) (4)
- Abrupt Onset of Refractory Heart Failure Associated With Light-Chain Amyloidosis in Hypertrophic Cardiomyopathy (2017) (4)
- Is heart failure with preserved ejection fraction a ‘dementia’ of the heart? (2021) (4)
- Determinants of discrepancies between two-dimensional echocardiographic methods for assessment of maximal left atrial volume (2017) (4)
- Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter (2022) (4)
- Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning (2022) (4)
- Epidemiology of cardiomyopathies: essential context knowledge for a tailored clinical work-up. (2020) (4)
- Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies (2022) (3)
- Reply: Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more? (2014) (3)
- Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation (2011) (3)
- Variational Gaussian Mixture Models with robust Dirichlet concentration priors for virtual population generation in hypertrophic cardiomyopathy: a comparison study (2021) (3)
- Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (2022) (3)
- Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy (2022) (3)
- Aetiologic diagnosis of ischaemic stroke in the emergency department: relevance for triage and clinical management (2000) (3)
- Feasibility of a Combined Mobile-Health Electrocardiographic and Rapid Diagnostic Test Screening for Chagas-Related Cardiac Alterations (2020) (3)
- Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy (2007) (3)
- Association of Premature Ventricular Contraction Burden on Serial Holter Monitoring With Arrhythmic Risk in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. (2022) (3)
- Letter regarding the article 'Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues. (2018) (3)
- Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama (2022) (3)
- Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy (2015) (3)
- Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center. (2022) (3)
- Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". (2019) (3)
- Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning (2021) (3)
- Mitochondrial Energetics and Ca2+-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy (2020) (3)
- Feasibility and outcome of mitral valve repair in patients with infective endocarditis (2020) (3)
- ECG-based screening: not only for athletes. (2007) (3)
- No heart is an island: hypertrophic cardiomyopathy, diabetes, and the test of time. (2018) (3)
- Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study (2022) (3)
- Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy (2022) (3)
- Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis. (2014) (2)
- Layman electrocardiographic screening using smartphone-based multiple‑lead ECG device in school children. (2022) (2)
- Leisure-time and competitive sport participation: a changing paradigm for HCM patients. (2023) (2)
- LACK OF PHENOTYPIC DIFFERENCES BY CMRI IN THE TWO MOST COMMON SARCOMERE PROTEIN GENE MUTATIONS IN HYPERTROPHIC CARDIOMYOPATHY (2013) (2)
- [Clinical pathway for cardiomyopathies: a genetic testing strategy proposed by ANMCO in Tuscany]. (2020) (2)
- Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy (2021) (2)
- Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management (2018) (2)
- Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. (2022) (2)
- Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy (2021) (2)
- A novel desmoplakin dominant mutation responsible for Carvajal/Naxos syndrome identified by exome sequencing (2013) (2)
- The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review (2021) (2)
- Exercise testing in hypertrophic cardiomyopathy: A pathophysiological goldmine with protean clinical implications. (2019) (2)
- Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis: A Network Meta-Analysis. (2022) (2)
- Abstract 13139: Prognostic Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy: An International Multicenter Study (2012) (2)
- ["African sickness" and the heart: the mystery of endomyocardial fibrosis]. (2011) (2)
- Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management. (2022) (2)
- Cardiomyopathies in children – inherited heart muscle disease (2018) (2)
- [Clinical pathway on pediatric cardiomyopathies: a genetic testing strategy proposed by the Italian Society of Pediatric Cardiology]. (2022) (2)
- THE MYOCARDIAL CONTRACTION FRACTION (MCF) IS ASSOCIATED WITH NYHA CLASS AS WELL AS DELAYED ENHANCEMENT BY CARDIAC MRI IN HYPERTROPHIC CARDIOMYOPATHY AND PREDICTS SUDDEN CARDIAC DEATH (2016) (2)
- Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy (2021) (2)
- Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures. (2021) (2)
- Creatine deficiency and heart failure (2021) (2)
- DOES FOCAL LATE GADOLINIUM ENHANCEMENT AT THE RIGHT VENTRICULAR INSERTION POINTS MATTER IN RISK STRATIFICATION FOR SUDDEN DEATH IN HYPERTROPHIC CARDIOMYOPATHY (2013) (2)
- The genetic architecture of left ventricular non-compaction reveals both substantial overlap with other cardiomyopathies and a distinct aetiology in a subset of cases (2020) (2)
- Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders (2021) (2)
- Pulmonary congestion during Exercise stress Echocardiography in Hypertrophic Cardiomyopathy (2021) (2)
- Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes (2022) (2)
- [Myocardial hypoperfusion due to microvascular dysfunction in hypertrophic cardiomyopathy: role of positron emission tomography]. (2009) (2)
- 121 Re-evaluating the genetic contribution of monogenic dilated cardiomyopathy (2019) (2)
- Poster Session 2 (2009) (2)
- Ventricular tachyarrhythmias and sudden cardiac death in light‐chain amyloidosis: a clash of cardio‐toxicities? (2021) (2)
- Contractile persistence in apical hypertrophic cardiomyopathy: Definitely too much of a good thing. (2018) (2)
- Prevalence and predictors of bradyarrhythmias requiring permanent pacing in patients with Anderson–Fabry disease (2022) (2)
- The effects of long-term migalastat treatment in Fabry disease patients previously treated with enzyme replacement therapy who have migalastat-amenable variants with low alpha-galactosidase A response in the in vitro migalastat amenability assay (2019) (1)
- Adverse prognostic value of supernormal left ventricular force noninvasively assessed by resting transthoracic echocardiography in hypertrophic cardiomyopathy (2022) (1)
- The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era (2020) (1)
- Response to Letter Regarding Article, “Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction” (2007) (1)
- Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy (2015) (1)
- The Importance of Sex Differences in Patients with Hypertrophic Cardiomyopathy - Tailoring Management and Future Perspectives. (2020) (1)
- Paradoxical prolongation of QT interval during exercise in patients with hypertrophic cardiomyopathy: cellular mechanisms and implications for diastolic function (2013) (1)
- Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure (2022) (1)
- Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. (2019) (1)
- Investigation on the high recurrence of the ATTRv-causing transthyretin variant Val142Ile in central Italy. (2022) (1)
- Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction (2016) (1)
- [Atrial fibrillation in hypertrophic cardiomyopathy: determinants, clinical course and management]. (2009) (1)
- Sex related differences in exercise performance in patients with hypertrophic cardiomyopathy: Hemodynamic insights through non-invasive pressure volume analysis. (2021) (1)
- Endocarditis with spondylodiscitis: clinical characteristics and prognosis (2021) (1)
- Hypertrophic Cardiomyopathy in Anderson-Fabry Disease (2007) (1)
- [Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling]. (2016) (1)
- The Italian Multicentric Study on Hypertrophic Cardiomyopathy: I. Natural History and Clinical Course of Unselected Patients (1998) (1)
- 4258Re-evaluating the genetic contribution of monogenic dilated cardiomyopathy (2019) (1)
- P2731Genetic ancestry analysis of the Italian founder population carrying the cardiac amyloidosis-causing variant Val122Ile in the transthyretin gene (2019) (1)
- THE EFFECT OF MAVACAMTEN ON CARDIOPULMONARY EXERCISE TESTING PERFORMANCE OF PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN EXPLORER-HCM (2022) (1)
- Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM (2023) (1)
- Abstract 11709: The Impact of Hypertension on Disease Expression in Hypertrophic Cardiomyopathy (2021) (1)
- Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (2020) (1)
- Life-Threatening Acute Pulmonary Thromboembolism Following Severe Carbon Monoxide Poisoning (2019) (1)
- Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy (2021) (1)
- Abstract 15324: Mavacamten Favorably Impacts Key Pathophysiologic Processes in Obstructive Hypertrophic Cardiomyopathy: Results From the EXPLORER-HCM Study (2020) (1)
- Abstract 14647: Stress Echocardiography Predicts Heart Failure Progression and Alters Management Strategies in Patients with Hypertrophic Cardiomyopathy (2014) (1)
- Two decades of genetic testing in hypertrophic cardiomyopathy in a single center: The additive value of extended next-generation sequencing panels lies in the early diagnosis of metabolic mimics (2018) (1)
- EFFICACY AND SAFETY OF AFICAMTEN AND DISOPYRAMIDE COADMINISTRATION IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: RESULTS FROM REDWOOD-HCM COHORT 3 (2022) (1)
- Comprehensive Risk Management in Arrhythmogenic Cardiomyopathy Associated With Autosomal Dominant Carvajal Syndrome (2020) (1)
- Multi-dimensional structure function relationships in human β-cardiac myosin from population scale genetic variation (2016) (1)
- Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance (2014) (1)
- Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. (2021) (1)
- [Disease progression and systolic dysfunction in patients with hypertrophic cardiomyopathy: genetic basis, pathophysiology and clinical presentation]. (2011) (1)
- The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. (2022) (1)
- The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence (2020) (1)
- Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy (2023) (1)
- Impediments to Heart Transplantation in Adults With MELASMT-TL1:m.3243A>G Cardiomyopathy. (2022) (1)
- Clinical scenarios of HCM-related mortality: Relevance of age and stage of disease at presentation. (2022) (1)
- Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis (2023) (1)
- Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument (2022) (1)
- Evolving Epidemiology of Hypertrophic Cardiomyopathy: Shifting the Focus From Instant to Lifetime Risk Awareness. (2022) (1)
- Sudden death in young athletes: Is it preventable? (2022) (1)
- Sudden cardiac death in cardiomyopathies: acting upon “acceptable” risk in the personalized medicine era (2022) (1)
- Abstract 14979: Progressive Heart Failure is Uncommon in Patients With Nonobstructive Hypertrophic Cardiomyopathy (2013) (1)
- P889Validation of a smartphone-camera based software for the identification of electrodes location on human chest (2018) (1)
- Hidden familial cardiomyopathies in children: Role of genetic testing. (2021) (1)
- Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease. (2022) (1)
- Microvascular Dysfunction in Hypertrophic Cardiomyopathy (2022) (1)
- Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply (2021) (1)
- Genetic causes of cardiomyopathies identified by Whole Exome Sequencing (2013) (0)
- Editors' page (2012) (0)
- Eosinophilic granulomatosis with polyangiitis, a new recurrent feature in an extremely rare disease (2020) (0)
- 217Comparative analysis of multiple leads smartphone electrocardiograph versus standard 12-leads electrocardiograph in patients with hypertrophic cardiomyopathy (2018) (0)
- [Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC)]. (2021) (0)
- Relationship between hyponatremia at hospital admission and cardiopulmonary profile at follow-up in patients with SARS-CoV-2 (COVID-19) infection (2022) (0)
- Abstract 14884: Obesity is a Major Driver of Obstruction and Heart Failure in Hypertrophic Cardiomyopathy: Results From the International Share Registry (2018) (0)
- A rare case of pediatric cardiomyopathy: Alström syndrome identified by gene panel analysis (2020) (0)
- Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy (0)
- Electrophysiological remodeling in primary versus secondary cardiac hypertrophy: a study in human cardiomyocytes (2022) (0)
- Genetic Tailoring of Electrophysiological Management in Hypertrophic Cardiomyopathy (2020) (0)
- 212Feasibility of cardiovascular screening in low-income settings using smartphone-based technologies (2018) (0)
- Prevalence and clinical correlates of clinical red flags for rare diseases in consecutive patients presenting with HCM phenotype (2022) (0)
- 158 Racial differences in val122Ile associated transthyretin cardiac amyloidosis (2021) (0)
- P2732Prevalence of electrocardiographic abnormalities in patients with cardiac amyloidosis (2019) (0)
- Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy (2000) (0)
- Long-term multisystemic efficacy with migalastat in ERT-naive and ERT-experienced patients with amenable variants (2022) (0)
- P2316Outcome of septal reduction therapies for obstructive hypertrophic cardiomyopathy in a high-flow referral centre with moderate volume procedural programmes (2017) (0)
- 501 Investigating the epidemiology of cardiac amyloidosis: design of the ‘cardiac amyloidosis registry’ (CARRY) (2021) (0)
- 2357Novel electrocardiographic parameters for the detection of Fabry Disease - A comparative multi-centre study (2018) (0)
- Abstract 16484: Primary Prevention Implantable Cardioverter Defibrillator Utilization for Hypertrophic Cardiomyopathy in US vs Non-US: Findings From the Share Registry (2020) (0)
- P2594Prevalence of cardiac amyloidosis by age-class in patients presenting with hypertrophic cardiomyopathy (2018) (0)
- Historical Perspective, Mechanism, and Clinical Significance of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy (2007) (0)
- Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption (2023) (0)
- RNA‐seq profiling reveals different pathways between remodeled vessels and myocardium in hypertrophic cardiomyopathy (2022) (0)
- Early- and delayed-afterdepolarizations as cellular promoter of ventricular fibrillation in hypertrophic cardiomyopathy (2022) (0)
- Focal LGE and Outcome in HCM JACC Cardiovascular Imaging 1 CLINICAL SIGNIFICANCE OF LATE GADOLINIUM ENHANCEMENT AT RIGHT VENTRICULAR ATTACHMENT TO VENTRICULAR SEPTUM IN HYPERTROPHIC CARDIOMYOPATHY Running title: Focal LGE and Outcome in HCM (2014) (0)
- LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (2023) (0)
- Prognostic value of reduced heart rate reserve during exercise stress-echocardiography in hypertrophic cardiomyopathy (2020) (0)
- [From loss to prevention: lessons to be learned from juvenile sudden death]. (2022) (0)
- Abstract 13503: Efficacy of Subcutaneous Implantable Cardioverter Defibrillator Defibrillation Testing in Hypertrophic Cardiomyopathy Patients at High Risk of Sudden Cardiac Death (2016) (0)
- Hypertrophic Cardiomyopathy Clinical Profile of Stroke in 900 Patients With Hypertrophic Cardiomyopathy (2001) (0)
- Abstract 1623: Coronary Angiodysplasia Associated With Hypertrophic Cardiomyopathy (2007) (0)
- P818Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: long-term results and clinical outcomes (2017) (0)
- Ventricular and Supraventricular Tachyarrhythmias Associated with Hypertrophic Cardiomyopathy (2012) (0)
- IMPACT OF OBESITY ON THE PHENOTYPE AND CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY (2012) (0)
- Chapter 29 – Arrhythmias Associated with Hypertrophic Cardiomyopathy (2005) (0)
- Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2 (2016) (0)
- Evidence that left ventricular outflow tract obstruction is a predictor of outcome in patients with hypertrophic cadiomyopathy (2003) (0)
- Clinical, functional and prognostic correlates of excess left ventricular force in hypertrophic cardiomyopathy (2022) (0)
- Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry (2022) (0)
- Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening (2021) (0)
- Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. (2021) (0)
- Molecular Modeling of Double cMyBP-C Mutation Resulting in End-Stage Hypertrophic Cardiomyopathy (2014) (0)
- Autopsy and genetic characterization of juvenile sudden cardiac arrest and death: the ToRSADE experience (2022) (0)
- 96-WEEK CARDIAC MAGNETIC RESONANCE (CMR) RESULTS OF TREATMENT WITH MAVACAMTEN FROM THE EXPLORER COHORT OF THE MAVA-LONG-TERM EXTENSION (LTE) STUDY IN PATIENTS (PTS) WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) (2023) (0)
- P3167Extra long term follow up of the original tuscany cohort of patients with hypertrophic cardiomyopathy (2018) (0)
- Abstract 15391: The Natural History of Asymptomatic and Mildly Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the Share Registry (2020) (0)
- Clinical phenotype and long-term outcome of patients with Anderson-Fabry disease followed at a multidisciplinary cardiomyopathy centre (2022) (0)
- Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy (2019) (0)
- P2728Prognostic impact of left atrial function in patients with cardiac amyloidosis: a cardiac magnetic resonance study (2019) (0)
- Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy (2023) (0)
- Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy (2015) (0)
- 073_16211-G2 Syncope Unit Management of Patients With Hypertrophic Cardiomyopathy and Syncope: Pathophysiologic Interpretation and Clinical Approach (2017) (0)
- Clinical Exome Sequencing Revealed a De Novo FLNC Mutation in a Child with Restrictive Cardiomyopathy (2022) (0)
- OPEN A CCESS Review article Regulation of intracellular Na 1 in health and disease: pathophysiological mechanisms and implications for treatment (2013) (0)
- Racial differences in val 122 Ile associated transthyretin cardiac amyloidosis (2021) (0)
- Abstract 11792: Low Penetrance Sarcomere Variants Indicate an Additive Genetic Risk Model in Hypertrophic Cardiomyopathy (2021) (0)
- Effects of myocardial fi brosis assessed by MRI on dynamic left ventricular out fl ow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis (2012) (0)
- Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal. (2016) (0)
- Comment on: Assessment of cardiac disease in MELAS requires comprehensive, prospective work-up. (2019) (0)
- Cellular determinants of arrhythmic rysk in hypertrophic cardiomyopathy (2021) (0)
- Beta-Adrenergic Response in Human HCM Myocardium: Effects of Ranolazine (2014) (0)
- P1457 Septic and aseptic valvular involvement in hypocomplementemic urticarial vasculitis syndrome (2020) (0)
- [Clinical relevance of genetic testing in hypertrophic cardiomyopathy]. (2011) (0)
- AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4) (2023) (0)
- Histopathology of the Mitral Valve Residual Leaflet in Obstructive Hypertrophic Cardiomyopathy (2023) (0)
- The Inglorious Art. (2022) (0)
- Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis (2022) (0)
- Long-term treatment with migalastat 150 mg every other day is associated with sustained cardiac efficacy and is well tolerated (2021) (0)
- Effect of migalastat on cardiac involvement in Fabry disease: preliminary results from MAIORA study (2021) (0)
- Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 1 (2016) (0)
- 983 COMPARISON OF DEMOGRAPHIC, CLINICAL, BIOCHEMICAL AND IMAGING AND IMAGING FINDINGS IN HYPERTROPHIC CARDIOMYOPATHY PROGNOSIS: A NETWORK META-ANALYSES (2022) (0)
- Determinants of Abnormal Excitation-Contraction Coupling in Cardiomyocytes from Patients with Hypertrophic Cardiomyopathy (2013) (0)
- Risk Assessment in Cardiac and Noncardiac Surgery in Older Patients (2017) (0)
- P4506Genetic basis of pediatric sarcomeric hypertrophic cardiomyopathy: impact on long term outcome (2017) (0)
- Hypertrophic cardiomyopathy: medical management of heart failure symptoms and arrhythmias (2018) (0)
- Abstract 16466: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (2018) (0)
- P900Electrocardiographic findings in Anderson-Fabry disease versus sarcomeric hypertrophic cardiomyopathy (2019) (0)
- Editors' page (2013) (0)
- Valve repair in patients with infective endocarditis (2020) (0)
- Prevalence of transthyretin-related amyloidosis in Tuscany: Data from the regional population-based registry. (2023) (0)
- Improving survival of chemotherapy-induced cardiomyopathy in the modern heart failure therapy era (2013) (0)
- Hypertrophic Cardiomyopathy at 50 (2009) (0)
- DETERMINANTS OF LEFT ATRIAL VOLUME IN HEALTHY INDIVIDUALS AND ATHLETES (2010) (0)
- Advances in Clinical Trials Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy Designing the Late Sodium Current Inhibition With Eleclazine on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Trial (2016) (0)
- Abstract 14117: Clinical Characteristics and Cardiovascular Outcomes in Childhood-Onset Hypertrophic Cardiomyopathy (2020) (0)
- 145Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy (2018) (0)
- Anxious/Depressive Symptoms Alter the Subjective Perception of Heart Failure Severity in Transthyretin Cardiac Amyloidosis. (2023) (0)
- Age-related differences and associated outcomes of S-ICD: insights from a large, european, multicenter, real-world registry (2022) (0)
- Prevalence of device-detected atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy (2020) (0)
- Abstract 4845: Hypertrophic Cardiomyopathy due to Sarcomere Gene Mutations is Associated with More Severe Derangement of Microvascular Function Compared to Myofilament Negative Disease (2008) (0)
- Rapid Fire – Genetics and epigenetics: news and views 487 (0)
- Predictors of adverse prognosis in patients with infective endocarditis in a surgical referral center (2020) (0)
- 1032-124 Coronary microvascular dysfunction and long-term left ventricular remodeling in hypertrophic cardiomyopathy (2004) (0)
- Abstract 10201: Efficacy of Mavacamten in Patients with Symptomatic Hypertrophic Cardiomyopathy: Sub-Group Analyses by Background Beta-Blocker Use from the EXPLORER-HCM and MAVA-LTE Studies (2021) (0)
- Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery. (2022) (0)
- Hypertrophic and Dilated Cardiomyopathy Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy (2005) (0)
- Editors' page (2013) (0)
- 1473Microvascular coronary disease and myocardial fibrosis within the spectrum of hypertrophic cardiomyopathy: a histopathologic study (2018) (0)
- Atrial Remodeling in Hypertrophic Cardiomyopathy (2017) (0)
- Electrocardiographic differences between Anderson-Fabry and sarcomeric hypertrophic cardiomyopathy and correlation with cardiac magnetic resonance (2020) (0)
- [Therapy of hypertrophic cardiomyopathy]. (1999) (0)
- Aortic Dilatation in Pediatric Patients with Bicuspid Aortic Valve: How the Choice of Nomograms May Change Prevalence (2023) (0)
- 263 GENETIC CAUSES OF CARDIOMYOPATHIES IN CHILDREN (2022) (0)
- Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy (2023) (0)
- Moving Forward in Pediatric Heart Failure: The Need for Cross-Fertilization Between Congenital Heart Disease and Cardiomyopathies (2018) (0)
- 580 INCIDENCE AND FACTORS ASSOCIATED WITH DE NOVO ATRIAL FIBRILLATION IN PATIENTS WITH WILD-TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS - A MULTICENTER STUDY (2022) (0)
- P392Preliminary evaluation of stress myocardial blood flow pattern in patients with apical hypertrophic cardiomyopathy candidate to be enrolled in the CARAPACE study. (2019) (0)
- Abstract 793: Identification and Characterization of a Novel Mutation in JPH2-Encoded Junctophilin-2 in an Italian Hypertrophic Cardiomyopathy Cohort (2007) (0)
- Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH 7 ( βMyosin βMyosin βMyosin Heavy Chain )Versus )Versus )Versus MYBPC 3 ( MyosinBinding MyosinBinding MyosinBinding Protein C )Related )Related )Related Hypertrophic Cardiomyopathy (2017) (0)
- Genetic characterization of juvenile sudden cardiac arrest and death in Tuscany: The ToRSADE registry (2022) (0)
- 110 Sex-related differences in clinical presentation and outcome of patients with cardiac transthyretin amyloidosis and light chain amyloidosis (2021) (0)
- Effect of Migalastat on cArdiac Involvement in FabRry Disease: MAIORA study (2023) (0)
- 310 CLINICAL COURSE AND CHARACTERISTICS OF ADVANCED HEART FAILURE ASSOCIATED WITH ARRHYTHMOGENIC CARDIOMYOPATHY (2022) (0)
- Can anthrop Q3 ology Q4 improve our care of inherited cardiac arrhythmias? A modest proposal (2016) (0)
- ong-Term Effects of Surgical Septal yectomy on Survival in Patients With bstructive Hypertrophic Cardiomyopathy (2005) (0)
- Diagnostic Delay in Arrhythmogenic Cardiomyopathy. (2023) (0)
- New York Heart Association Functional Class And Mortality In Obstructive Hypertrophic Cardiomyopathy (2022) (0)
- Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy? (2017) (0)
- Heterogeneous mechanisms of pulmonary congestion in hypertrophic cardiomyopathy unmasked by comprehensive exercise stress echocardiography (2022) (0)
- Abstract 3357: Pattern and Degree of Reverse Remodelling Following Extended Septal Myectomy for Hypertrophic Cardiomyopathy: An MRI Study (2009) (0)
- 749 Clinical profile and outcome of patients with Anderson–Fabry disease followed at a multidisciplinary cardiomyopathy centre (2021) (0)
- P2315The Portuguese registry of hypertrophic cardiomyopathy (PRO-HCM): global results (2017) (0)
- Apical papillary muscle displacement is a prevalent feature and a phenotypic precursor of apical hypertrophic cardiomyopathy. (2023) (0)
- Computer-assisted evaluation of vessels tortuosity in Fabry disease (2018) (0)
- 686 ASSOCIATION OF PREGNANCY WITH THE NATURAL HISTORY OF WOMEN DIAGNOSED WITH HYPERTROPHIC CARDIOMYOPATHY (2022) (0)
- 158 Racialdifferencesinval122Ileassociatedtransthyretincardiac amyloidosis (2021) (0)
- The Missense E258K-MyBP-C Mutation Increases the Energy Cost of Tension Generation in Both Ventricular and Atrial Tissue from HCM Patients (2018) (0)
- Mid-ventricular obstruction in hypertrophic cardiomyopathy: a signal void. (2022) (0)
- Comparative analysis of a 4-lead portable smartphone based electrocardiograph versus standard 12-lead electrocardiograph for cardiovascular screening in low-income settings (2016) (0)
- 479Age-specific prevalence of cardiac structural alterations in a large consecutive cohort of athletes by pre-participation screening (2018) (0)
- Sex Disaggregated Analysis of Risk Factors for Adverse Outcomes in Hypertrophic Cardiomyopathy (2022) (0)
- 586 BODY WEIGHT AND MICROVASCULAR DYSFUNCTION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AT LOW CARDIOVASCULAR RISK REFERRED TO POSITRON EMISSION TOMOGRAPHY (2022) (0)
- P4497Accuracy of LGE-CMR compared with histometric quantification of myocardial fibrosis in transplanted hearts of end-stage HCM (2017) (0)
- Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis. (2023) (0)
- The Italian Multicentric Study on Hypertrophic Cardiomyopathy: II. Prognostic Assessment in Symptomatic Patients (1998) (0)
- P1243Comparison of long-term clinical course and outcome of MYBPC3 - versus MYH7 - related hypertrophic cardiomyopathy (2019) (0)
- 1152 INVESTIGATION ON THE HIGH INCIDENCE OF THE ATTRV-CAUSING TRANSTHYRETIN VARIANT VAL142ILE IN CENTRAL ITALY (2022) (0)
- Abstract 2161: Left Ventricular Dysfunction and Outcome in Myofilament Positive and Myofilament Negative Hypertrophic Cardiomyopathy (2006) (0)
- 486 ELECTROCARDIOGRAPHIC EVOLUTION IN ANDERSON-FABRY PATIENTS ON DISEASE SPECIFIC THERAPY (2022) (0)
- The coronary microcirculation in sepsis: not of micro-importance (2020) (0)
- [Ventricular storm in a young man with primary hypokinetic dilated cardiomyopathy: why thinking of sarcoidosis?] (2019) (0)
- Correction to: Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy (2022) (0)
- Impaired cardiopulmonary test performance as a marker of early functional impairment in patients with Anderson-Fabry disease (2021) (0)
- Bayesian Inference-Based Gaussian Mixture Models With Optimal Components Estimation Towards Large-Scale Synthetic Data Generation for In Silico Clinical Trials (2022) (0)
- Corrigendum to "Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis" [International Journal of Cardiology Volume 357, 15 June 2022, Pages 88-94]. (2022) (0)
- Abstract 16333: Racial Differences in Pressure-volume Relationships in Val122Ile Associated Cardiac Amyloidosis (2020) (0)
- Herz Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy (2006) (0)
- Abstract 14781: Computational Prediction of Protein Subdomain Stability as a Novel Approach to Cardiac Myosin Binding ProteinC Variant Adjudication and Clinical Risk Stratification in Hypertrophic Cardiomyopathy (2020) (0)
- P3545Efficacy and safety of dysopiramide in patients with obstructive hypertrophic cardiomyopathy (2018) (0)
- Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy (2022) (0)
- Images in cardiology Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy (2015) (0)
- Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations (2020) (0)
- Heritability in genetic heart disease (2019) (0)
- 124Predictive value of classic sudden death risk factors in pediatric-onset hypertrophic cardiomyopathy (2017) (0)
- Does a Maximum Left Ventricular Thickness Greater than 30 mm Identify Patients with Hypertrophic Cardiomyopathy at Risk of Sudden Death (2004) (0)
- Prevalence of adverse cardiovascular events in pediatric cardiomyopathies: an analysis of 110 patients followed at a long-standing tertiary care paediatric centre (2020) (0)
- Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression (2010) (0)
- Abstract 16889: Ventricular Arrhythmia (VA) in Hypertrophic Cardiomyopathy (HCM): Novel Arrhythmia Risk Stratification Using T1 Mapping, Late Gadolinium Enhancement MRI (LGE-MRI), and Computational Modeling (2017) (0)
- Validation of a multiple‑lead smartphone-based electrocardiograph with automated lead placement for layman use in patients with hypertrophic cardiomyopathy. (2023) (0)
- Report on the 2nd Florence International Symposium on Advances in Cardiomyopathies: 9th meeting of the European Myocardial and Pericardial Diseases WG of the ESC (2012) (0)
- A molecular modeling approach for understanding mechanism of disease causing mutations in domain C1 of cardiac myosin binding protein C (2013) (0)
- Rare X-linked storage heart diseases are tougher on men but not kind to women. (2019) (0)
- Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring. (2022) (0)
- A “smart” Imputation Approach for Effective Quality Control Across Complex Clinical Data Structures (2022) (0)
- 465 Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey (2021) (0)
- Editors’ page (2012) (0)
- Late sodium current blockers with different selectivity reduce the electrical and mechanical dysfunction in the myocardium of patients with hypertrophic cardiomyopathy (2015) (0)
- Editors' page (2013) (0)
- Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions (2023) (0)
- P4235Telemedicine cardiovascular screening program in low-income settings by smartphone based technology (2018) (0)
- 1032-119 Prevalence of mutations in the cardiac myosin-binding protein C gene among tuscan patients with hypertrophic cardiomyopathy (2004) (0)
- Electrocardiographic findings in Anderson-Fabry patients on disease specific therapy: can treatment prevent ECG changes? (2022) (0)
- CORRELATION OF ECHOCARDIOGRAPHIC FINDINGS WITH SYMPTOMS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS (2019) (0)
- Development and validation of a smartphone based app to support the differential diagnosis in patients with primary left ventricular hypertrophy (2022) (0)
- Clinical profile and outcome of cardiomyopathies in infants and children seen at a tertiary centre. (2022) (0)
- 751 CANCER TREATMENT RELATED COMPLICATIONS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2022) (0)
- Prevalence and predictors of bradyarrhythmias requiring Permanent Pacing in patients with Anderson-Fabry disease. (2021) (0)
- Exercise-induced pulmonary hypertension in hypertrophic cardiomyopathy: a combined cardiopulmonary exercise test—echocardiographic study (2021) (0)
- Anti-arrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: The importance of optimal beta-blocker dose titration. (2021) (0)
- FEMALE GENDER IS ASSOCIATED WITH MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (2012) (0)
- 583 DEFORMATION MAP OF LEFT VENTRICULAR STRAIN: COMPARISON BETWEEN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AND CONTROLS WITHOUT SIGNIFICANT CORONARY ARTERY STENOSIS (2022) (0)
- ECG as a storytelling of cardiac involvement evolution in Anderson Fabry disease (2022) (0)
- Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis (2022) (0)
- Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: The Times They Are a-Changin'. (2021) (0)
- [Assessment of left ventricular outflow tract obstruction according to the latest European guidelines on hypertrophic cardiomyopathy]. (2015) (0)
- Inflammation across the spectrum of hypertrophic cardiac phenotypes. (2023) (0)
- 965 PROGNOSTIC VALUE OF CARDIOPULMONARY EXERCISE TESTING IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (2022) (0)
- Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning (Preprint) (2021) (0)
- Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center (2018) (0)
- Stage-specific therapy for hypertrophic cardiomyopathy (2023) (0)
- Lifetime mortality associated with hypertrophic cardiomyopathy: 28-year outcome of an historical cohort (2020) (0)
- Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions (2020) (0)
- Abstract 16784: Participation in Thrill-Seeking Activities for Hypertrophic Cardiomyopathy Patients (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Iacopo Olivotto?
Iacopo Olivotto is affiliated with the following schools:
